Accuray Q1 2027 earnings

ARAY · 2026-11-04 16:03 AMC ET · 8-K on SEC · 10-Q on SEC

GAAP net income turned positive to $10.1 million, but adjusted EBITDA remained negative at $2.5 million, and product revenue declined 26% YoY.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$86.5M-8%—Ex. 99.1, income statement
EPS (GAAP)$0.07+0.25—Ex. 99.1, income statement
EPS (adjusted)-$0.10+0.08—Ex. 99.1, income statement
Net income$10.1M+$31.8M—Ex. 99.1, income statement
Adj. EBITDA$2.5M+$6.6M—Ex. 99.1, income statement
Adj. EBITDA margin2.9%+7.0 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Products$27.3M-26%31.6%Decrease driven by lower product revenue
Services$59.2M+4%68.4%Increase driven by higher service revenue

Margins and costs

  • Gross margin 30.1% (prior 28.8%, change +1.3 pp)
  • Operating expenses $62.6M (+63% YoY)
  • One-offs in the quarter Gain on extinguishment of debt $59.6M; Goodwill impairment $35.4M; Restructuring charges $0.4M
  • Effective tax rate 4.9% (prior-year 2.2%)
  • Non-GAAP bridge Adds back depreciation, stock-based compensation, interest expense, gain on debt extinguishment, goodwill impairment, warrant liability changes, restructuring, and post-financing costs

KPIs

MetricActualPrior quarterPrior yearChange
Gross product orders$19.8M$37.7M (Q4 FY2026)$39.6M-50% vs prior quarter, -50% vs prior year
Book to bill ratio0.70.9 (Q4 FY2026)1.1-0.2 pp vs prior quarter, -0.4 pp vs prior year
Order backlog$272.0M$312.5M (Q4 FY2026)$396.0M-13% vs prior quarter, -31% vs prior year
Cash and cash equivalents$42.3M$40.6M$57.4M+$1.7M vs prior quarter, -$15.1M vs prior year

Guidance

not stated in the 8-K

What drove it

  • Revenue story Total net revenue decreased 8% YoY to $86.5M; product revenue decreased 26% YoY to $27.3M, while service revenue increased 4% YoY to $59.2M.
  • EPS story GAAP net income turned positive to $10.1M ($0.07 per share) driven by a $59.6M gain on debt extinguishment and a $35.4M goodwill impairment charge, while adjusted EPS remained negative at -$0.10.
  • One-off check Gain on extinguishment of debt $59.6M; Goodwill impairment $35.4M; Restructuring charges $0.4M

The good

  • Service revenue increased 4% YoY
  • Adjusted EBITDA margin improved 7.0 pp YoY to 2.9%
  • Cash and cash equivalents increased $1.6M sequentially

The bad

  • Product revenue decreased 26% YoY
  • Gross product orders decreased 50% YoY to $19.8M
  • Book to bill ratio declined to 0.7
  • Order backlog decreased 31% YoY to $272.0M

The ugly

  • none

Open questions

  • Reason for the significant decline in gross product orders and book-to-bill ratio
  • Impact of the goodwill impairment on future earnings
  • Long-term sustainability of the adjusted EBITDA margin at 2.9%
Full release

Accuray (ARAY) earnings release, November 4, 2026

Accuray Inc (ARAY) · Form 8-K, Item 2.02 · Filed · SEC filing

Accuray Reports Fiscal

2027

First

Quarter Financial Results

MADISON, Wisconsin,

November 4, 2026 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended

September 30, 2026.

Key Highlights

"As I said on our last call, fiscal 2026 was a year of transformation, and fiscal 2027 is about execution," said Steve La Neve, President and Chief Executive Officer of Accuray. "During the first quarter, we made progress across several areas. Service margins improved, operating expenses remained well controlled, we strengthened our financial position, and we advanced our innovation roadmap through strategic partnerships with RaySearch and Samsung NeuroLogica. By combining our strengths in precision treatment delivery and real-time motion management with enhanced imaging and adaptive capabilities, we believe we can further differentiate our platforms and deliver greater value for clinicians and patients."

Mr. La Neve continued, "At the same time, we see a clear opportunity to improve product and order performance. The customer engagement we saw at ASTRO, the growing clinical evidence supporting precision radiation therapy, and the opportunities created by our innovation strategy reinforce our confidence in the direction we are taking. Our focus now is on turning that engagement into orders and revenue, and on pairing the operating discipline we have built with stronger commercial performance. We know what we need to execute, and our team is focused on delivering."

Fiscal

First

Quarter Results

Total net revenue was

$86.5 million in the first quarter of fiscal 2027, or a decrease of⁸ percent, as compared to

$93.9 million in the prior fiscal year first quarter. Product revenue was

$27.3 million in the first quarter of fiscal 2027, or a decrease of²⁶ percent, as compared to

$37.2 million in the prior fiscal year first quarter. Service revenue was

$59.2 million in the first quarter of fiscal 2027, or an increase of⁴ percent, as compared to

$56.8 million in the prior fiscal year first quarter.

Total gross profit was

$26.1 million in the first quarter of fiscal 2027, or

30.1 percent of total net revenue, as compared to a total gross profit of

$27.0 million, or

28.8 percent of total net revenue, in the prior fiscal year first quarter. The increase in gross margin rate was primarily due to a higher service gross margin rate, reflecting ongoing pricing initiatives.¹

Operating expenses were

$62.6 million in the first quarter of fiscal 2027, including a

$35.4 million non-cash goodwill impairment charge. Excluding the goodwill impairment charge, operating expenses were

$27.2 million, a decrease of²⁹ percent compared to the prior fiscal year first quarter. Operating expenses in the first quarter of fiscal 2027 included

$0.4 million in restructuring charges, as compared to

$2.8 million in the prior year. Excluding goodwill impairment, o perating expenses decreased across all operating expense categories as a result of the Company’s disciplined execution of its transformation initiatives.

The Company recognized a gain on extinguishment of debt of approximately

$59.6 million in connection with its July 2026 financing transaction. The transaction added a substantive contingent conversion feature to the outstanding Term Loan B and Delayed Draw Term Loan, resulting in extinguishment accounting and initial recognition of the replacement loans at fair value. The gain primarily reflected the difference between the net carrying amounts of the existing loans and the fair value of the replacement loans. Recognition of the gain did not depend on completion of the debt-for-equity exchange, which remained subject to closing conditions at September 30, 2026, including requisite stockholder approval and implementation of a reverse stock split.

Net income was

$10.1 million in the first quarter of fiscal 2027, or a diluted net income of

$0.07 per share, including the

$59.6 million non-cash gain on extinguishment of debt and

$35.4 million non-cash goodwill impairment charge. Excluding both items, net loss was

$14.0 million in the first quarter of fiscal 2027, or a diluted net loss of

$0.10 per share, as compared to a net loss of

$21.7 million, or a diluted net loss of

$0.18 per share, in the prior fiscal year first quarter. Adjusted EBITDA was

$2.5 million in the first quarter of fiscal 2027, as compared to a negative adjusted EBITDA of

$4.1 million in the prior fiscal year first quarter.

Gross product orders were

$19.8 million i n the first quarter of fiscal 2027 as compared to

$39.6 million in the prior fiscal year first quarter. The book to bill ratio was

0.7 in the first quarter of fiscal 2027, as compared to

1.1 the prior fiscal year first quarter. Order backlog as of

September 30, 2026 was

$272.0 million, which is approximately³¹ percent lower than at the end of the prior fiscal year first quarter.

Total cash, cash equivalents and restricted cash as of quarter end amounted to

$50.4 million, an increase of

$1.6 million from June 30, 2026.

Fiscal Year

2027

Financial Guidance

The Company continues not to provide formal revenue or Adjusted EBITDA guidance for fiscal 2027. After a fiscal 2026 focused on transformation, its priority in fiscal 2027 is execution. That means building on the progress made in service margins, cost structure and financial flexibility, and turning commercial engagement into stronger product revenue and order performance. With a more efficient business model in place, the Company believes it is well positioned to execute on its strategic priorities in fiscal 2027.

Conference Call Information

Accuray will host a conference call beginning at 3:30 p.m. CT/4:30 p.m. ET today to discuss results for the first..arter of fiscal 2027 as well as recent corporate developments. Conference call dial-in information is as follows:

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray’s website, www.accuray.com. There will be a slide presentation accompanying today’s event which can also be accessed on the company’s Investor Relations page at www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion and will be available for seven days. The replay number i s (855) 669-9658 (USA), or (412) 317-0088 (International), Conference ID: 7745341. A n archived webcast will also be available on Accuray’s website until Accuray announces its results for the second quarter of fiscal 2027.²

Use of Non-GAAP Financial Measures

Accuray reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”) and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA and revenue on a constant currency basis.

Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, changes to the fair value of warrant liability, gain on extinguishment of debt, goodwill impairment and restructuring charges (“adjusted EBITDA”). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.³

Financial statements

Income Statement

Three Months Ended — (Unaudited) (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Net revenue:
Products27,34437,161
Services59,17956,781
Total net revenue86,52393,942
Cost of revenue:
Cost of products22,04729,422
Cost of services38,39237,509
Total cost of revenue60,43966,931
Gross profit26,08427,011
Operating expenses:
Research and development7,81111,218
Selling and marketing8,68111,699
General and administrative10,31912,596
Restructuring3832,811
Goodwill impairment35,392
Total operating expenses62,58638,324
Loss from operations-36,502-11,313
Income from equity method investment, net114439
Interest expense-11,828-8,052
Gain on extinguishment of debt59,563
IEEPA refund financing costs-55
Loss from change in fair value of warrant liability-707-1,874
Other income (expense), net66-407
Income (loss) before provision for income taxes10,651-21,207
Provision for income taxes517471
Net income (loss)10,134-21,678
Net income (loss) per share - basic0.07-0.18
Net income (loss) per share - diluted0.07-0.18
Weighted average common shares used in computing net income (loss) per share:
Basic138,202118,946
Diluted139,256118,946

Income Statement

Three Months Ended — (Unaudited) (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
GAAP net income (loss)10,134-21,678
Depreciation and amortization (a)2,0271,676
Stock-based compensation1,1212,515
Interest expense, net (b)11,6977,780
Gain on extinguishment of debt-59,563
Goodwill impairment35,392
Provision for income taxes517471
Loss from change in fair value of warrant liability7071,874
IEEPA refund financing costs55
Restructuring charges3832,811
Post-financing costs441
Adjusted EBITDA2,470-4,110

Balance Sheet

September 30, 2026 — (Unaudited) (in thousands)

September 30, 2026June 30, 2026
Current assets:
Cash and cash equivalents42,25440,623
Restricted cash827611
Accounts receivable, net50,34367,409
Inventories, net146,083147,075
Prepaid expenses and other current assets26,34231,783
Deferred cost of revenue199276
Total current assets266,048287,777
Noncurrent assets:
Property and equipment, net25,91627,316
Investment in joint venture5,3115,024
Operating lease right-of-use assets, net26,13127,512
Goodwill22,52457,911
Long-term restricted cash7,3027,533
Other assets36,82330,603
Total assets390,055443,676
Current liabilities:
Accounts payable33,05040,554
Accrued compensation12,73215,666
Operating lease liabilities, current7,8498,236
Other accrued liabilities23,24432,235
Customer advances9,57810,401
Deferred revenue, current76,95382,813
Short-term debt, net6,7001,500
Total current liabilities170,106191,405
Noncurrent liabilities:
Operating lease liabilities, non-current26,45327,768
Long-term other liabilities6,1075,477
Warrant liability6,4892,427
Deferred revenue, non-current24,83628,530
Investor deposit obligation7,975
Long-term debt, net94,972146,370
Total liabilities336,938401,977
Stockholders' equity:
Common stock120119
Additional paid-in capital612,552613,559
Accumulated other comprehensive loss-1,223-3,513
Accumulated deficit-558,332-568,466
Total stockholders' equity53,11741,699
Total liabilities and stockholders' equity390,055443,676

Cash Flow

From the 10-Q · Three Months Ended — (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Cash flows from operating activities
Net income (loss)10,134-21,678
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Goodwill impairment35,392
Depreciation and amortization2,0271,676
Share-based compensation1,1212,515
Amortization of debt financing costs and discount for warrants issued to lenders4,7311,905

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements that are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations and financial position, including expectations regarding: the company’s service margins, backlog, age-ins and age-outs, cancellations of contracts and foreign currency impacts; the expected impact of changes to strengthen the company’s commercial organization and improve execution; expectations regarding the effects of the global macroeconomic conditions on the company’s financial results and business; the company’s ability to further differentiate its platforms and deliver greater value; the company’s ability to execute on delivering stronger commercial performance; the company’s ability to execute on its strategic priorities in fiscal 2027; expectations related to the company’s credit facilities; the expected benefits from the transformation plan and refinancing transactions; the ability to achieve the objectives of the transformation plan; the company’s ability to deliver sustained performance and execute on its strategies and objectives, including related to its transformation efforts; the company’s ability to improve sales and drive margin expansion; opportunities to accelerate top-line growth and expand profitability; expectations related to the amount and timing of realizing deferred margin from the company’s China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding installed base growth; and the company’s ability to improve execution, drive sustainable, profitable growth, while creating long-term value for patients, providers and shareholders. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “may,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; effects related to international tariffs; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the company’s ability to successfully implement its transformation plan; the effect of enhanced international tariffs on the company; the company’s ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; geopolitical uncertainty, including armed conflict or political instability in the Middle East or other regions in which the company or its customers operate, and the effect of such conditions on the timing of system installations, customer site readiness, service revenue recognition, and the ability to complete transactions in affected markets; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading “Risk Factors” in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on August 27, 2026, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

###

Financial Tables to Follow⁴

Accuray Incorporated

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)⁵

Accuray Incorporated

Condensed Consolidated Balance Sheets

(in thousands)

(Unaudited)⁶

Accuray Incorporated

Summary of Orders and Backlog

(in thousands, except book to bill ratio)

(Unaudited)

(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period.

Accuray Incorporated

Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA

(in thousands)

(Unaudited)

(a) Consists of depreciation on property and equipment and amortization of capitalized software and intangibles.

(b) Consists of interest expense net of interest income.⁷

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.